Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | STAT5B | P51692 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22213898 | 0.86 | NPSR1 (0.45) | NPSR1STAT5BALDH1A1SMN1; SMN2POLB | |
| SCHEMBL8936009 | 0.81 | GAA (0.37) | STAT5BALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL25745097 | 0.79 | KMT2A (0.33) | STAT5BALDH1A1LMNAKDM4EKMT2A | |
| SCHEMBL8936043 | 0.76 | NPSR1 (0.42) | NPSR1STAT5BALDH1A1SMN1; SMN2POLB | |
| SCHEMBL30281258 | 0.75 | CA12 (0.45) | ALDH1A1KMT2ACA12CA1CA2 | |
| SCHEMBL8936020 | 0.74 | LMNA (0.34) | ALDH1A1SMN1; SMN2LMNAL3MBTL1HTT | |
| SCHEMBL17950597 | 0.73 | NPSR1 (0.48) | NPSR1STAT5BALDH1A1SMN1; SMN2POLB | |
| SCHEMBL13343501 | 0.73 | KMT2A (0.50) | NPSR1ALDH1A1SMN1; SMN2POLBTSHR | |
| SCHEMBL25528246 | 0.71 | NPSR1 (0.45) | NPSR1STAT5BALDH1A1SMN1; SMN2POLB | |
| SCHEMBL29253024 | 0.71 | NPSR1 (0.41) | NPSR1STAT5BALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207206-B2 | (S,R)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent | ONCONOX APS (DK) | 2012-06-26 | — | — | US | disclosed |
| US-8207206-B2 | (S,R)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent | ONCONOX APS (DK) | 2012-06-26 | — | — | US | disclosed |
| US-20100305176-A1 | (S,R.)-3-PHENYL-4,5 DIHYDRO-5-ISOXAZOLE ACETIC ACID-NITRIC OXIDE AND USE THEREOF AS ANTI-CANCER AND ANTIVIRAL AGENT | GANIAL IMMUNOTERAPEUTICS INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305176-A1 | (S,R.)-3-PHENYL-4,5 DIHYDRO-5-ISOXAZOLE ACETIC ACID-NITRIC OXIDE AND USE THEREOF AS ANTI-CANCER AND ANTIVIRAL AGENT | GANIAL IMMUNOTERAPEUTICS INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305176-A1 | (S,R.)-3-PHENYL-4,5 DIHYDRO-5-ISOXAZOLE ACETIC ACID-NITRIC OXIDE AND USE THEREOF AS ANTI-CANCER AND ANTIVIRAL AGENT | MAPK7, CASP7, ANXA7 | NPSR1 2413/4885STAT5B 161/4885ALDH1A1 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.